BRD4 Recombinant Protein: A Core Transcriptional Regulator of the BET Family and a Key Tool for Tumor-Targeted Research

Author: Senior Product Manager of UA Views：9

This article focuses on the molecular characteristics and transcriptional regulatory functions of bromodomain-containing protein 4 (BRD4), systematically elaborating its structural basis as a BET family member composed of two tandem bromodomains, BD1 and BD2, analyzing the molecular mechanisms by which BRD4 participates in the transcription of oncogenes such as MYC, BCL2, and BCL6 through binding with RNA polymerase II and the positive transcription elongation factor P-TEFb, and exploring the association between BRD4 dysregulation and hematological malignancies, breast cancer, and colon cancer, as well as the antitumor effects of its targeted inhibition.

Recent Advances
Product Information

Recent Advances

BRD4 Recombinant Protein: A Core Transcriptional Regulator of the BET Family and a Key Tool for Tumor-Targeted Research

Brief Introduction: This article focuses on the molecular characteristics and transcriptional regulatory functions of bromodomain-containing protein 4 (BRD4), systematically describing its structural basis as a BET family member composed of two tandem bromodomains, BD1 and BD2. It analyzes the molecular mechanism by which BRD4 participates in the transcription of oncogenes such as MYC, BCL2, and BCL6 through binding to RNA polymerase II and the positive transcription elongation factor P-TEFb, and discusses the association between BRD4 dysregulation and blood cancers, breast cancer, and colon cancer, as well as the antitumor effects of its targeted inhibition.

I. Molecular Structure of BRD4 and Its Positioning within the BET Family.

BRD4, namely bromodomain-containing protein 4, is a member of the BET family. BRD4 is a widely expressed nuclear protein with a molecular weight of 200 kDa, containing two tandem bromodomains, BD1 and BD2, which are structurally conserved but functionally distinct, as well as an ET domain. The core function of bromodomains is to recognize and bind to acetylation modifications on histone lysine residues, which is the structural basis for BRD4 to be recruited to actively transcribed chromatin regions. Although BD1 and BD2 are highly conserved in structure, differences exist in the amino acid composition and conformational flexibility of their ligand-binding pockets. This difference determines their differential affinity for acetylated histones and different small-molecule ligands, and is also a structural consideration that must be taken into account when developing subtype-selective inhibitors. The ET domain participates in the interaction of BRD4 with other transcriptional regulatory factors, jointly maintaining its function as a transcriptional co-regulator.

II. Core Mechanism of BRD4 in Oncogene Transcriptional Regulation.

BRD4 protein can bind to RNA polymerase II and the positive transcription elongation factor P-TEFb, jointly participating in the transcription of oncogenes such as MYC, BCL2, and BCL6. From a molecular mechanism perspective, BRD4 binds to acetylated histones in promoter and enhancer regions through its bromodomains, thereby recruiting the P-TEFb complex, which phosphorylates the C-terminal domain of RNA polymerase II, thereby relieving the blockade of transcription elongation and promoting efficient elongation of RNA polymerase II from the proximal promoter into the gene body. This functional chain of "acetylation recognition—P-TEFb recruitment—transcription elongation activation" makes BRD4 a core node regulating the expression of key oncogenes such as MYC. Since MYC, BCL2, and BCL6 drive cell proliferation and survival in various malignant tumors, functional abnormalities of BRD4 can directly lead to transcriptional dysregulation of these oncogenes, thereby promoting tumor development and progression.

III. Association between BRD4 Dysregulation and Multiple Cancers.

Studies have shown that dysregulation of BRD4 expression is associated with the formation of multiple cancer diseases, including blood cancers, breast cancer, and colon cancer. In hematological malignancies, abnormal activation of BRD4 is closely associated with MYC-driven leukemia and lymphoma; in breast cancer, BRD4 participates in regulating the network of estrogen receptor signaling pathways and MYC expression; in colon cancer, BRD4 has likewise been found to be a key regulator of tumor cell growth. In addition, BRD3 and BRD4 erroneously fuse with the nuclear protein NUT in the testis, leading to the occurrence of NUT midline carcinoma. This fusion event connects the bromodomains of BRD4 with the transcriptional regulatory region of the NUT protein, forming an abnormal fusion transcription factor that drives a highly aggressive rare tumor. The broad involvement of BRD4 in multiple cancers makes it one of the most closely watched targets in the field of epigenetic targeted therapy.

IV. Antitumor Effects of Targeting BRD4 and Functional Validation.

Through targeted inhibition of BRD4, tumor cell apoptosis, i.e., slowed proliferation, can be induced, thereby achieving antitumor effects. The molecular logic of this antitumor effect lies in the fact that after BRD4 function is inhibited, the transcriptional elongation of oncogenes such as MYC, BCL2, and BCL6 is blocked, their protein expression levels decrease, and tumor cells lose the driving signals required to maintain rapid proliferation and anti-apoptosis, thereby undergoing apoptosis or proliferation arrest. At the level of functional validation, sequential screening using CRISPR/Cas9 technology identified BRD4 as a key regulator of colon cancer cell growth. CRISPR/Cas9 is an adaptive immune defense formed by bacteria and archaea during long-term evolution, which can be used to combat invading viruses and exogenous DNA. This system integrates fragments of invading phage and plasmid DNA into CRISPR and uses corresponding CRISPR RNAs to guide the degradation of homologous sequences, thereby providing immunity. Applying this gene-editing tool to genome-wide screening enables researchers to systematically evaluate the necessity of each gene for colon cancer cell growth in an unbiased manner. BRD4 was identified as a key regulator in the screening, providing direct genetic evidence for its role as a therapeutic target for colon cancer.

V. Conclusion.

In BRD4-related basic research and the development of epigenetic targeted drugs, high-quality recombinant BRD4 protein is a core tool for elucidating the binding mechanism between its bromodomains and acetylated histones, evaluating the activity of BD1- and BD2-selective inhibitors, and conducting protein-protein interaction studies. The His tag facilitates efficient purification through immobilized metal affinity chromatography and enables detection and capture via anti-His tag antibodies. In response to the needs of BRD4 functional research and epigenetic drug development, UIA provides BRD4 His Tag Protein, Human. This product is suitable for application scenarios such as binding activity analysis of BRD4 bromodomains with acetylated histones and small-molecule ligands, in vitro screening and evaluation of BD1- and BD2-subtype-selective inhibitors, mechanistic research on the interactions of BRD4 with P-TEFb and RNA polymerase II, and functional exploration of NUT midline carcinoma-related fusion proteins.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next